Compare Quest Diagnostics Inc (DGX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Ryanair Holdings plc — how do they compare? Quest Diagnostics Inc trades at $237.64 (market cap $26.21B), while Ryanair Holdings plc trades at $60 (market cap $29.63B). The key difference: Quest Diagnostics Inc and Ryanair Holdings plc are close in size by market cap, and Ryanair Holdings plc pays the higher dividend (1.51%). Which is the better fit depends on your goals.
| DGX | RYAAY | |
|---|---|---|
Market Cap | $26.21B | $29.63B |
Sector | Health | Industrials |
52-Week High | $238.50 | $73.82 |
52-Week Low | $173.49 | $53.24 |
Enterprise Value | $31.97B | $26.61B |
Dividend Yield | 1.45% | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
RYAAY trades at $60.63, up 1.88% today, but faces a bearish technical signal with support at $58. Fundamentally, it shows strong profitability with a 12.13% net margin and a reasonable P/E of 14.37. Recent Q1 2026 earnings beat expectations despite a 34% profit decline due to lower fares and higher fuel costs (Reuters, 2026-07-20). The company maintains a robust balance sheet with $3.96B in cash and announced a strategic AI partnership with Google Cloud to enhance operations.
The outlook is mixed; analyst consensus is bullish (62.5% buy ratings), citing long-term advantages from industry consolidation and a strong financial position. However, near-term risks include volatile fuel prices, competitive fare pressures, and geopolitical tensions affecting travel demand. The stock presents a value opportunity for patient investors, but requires monitoring of operational execution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
